cells

B-lymphoblastoid cells from the bone marrow of a woman with multiple myeloma but cells appear to be 'EBV+ B-lymphoblastoid cells' rather than myeloma-derived cells (see also Pellat-Deceunynk et al., Blood 86: 4001-4002, 1995)

Cell Type:

B cell

Tissue Origin:

bone marrow

Species:

human

Research Area:

Cancer Research/Cell Biology

Immunotherapy / Hematology

Cell Characteristics:

Suspension

Transfection Information

Lonza Optimized Protocol
Optimization Guideline

Filter:

The table below shows data for the cell type and Nucleofector™ Platform selected. Those data are either based on Lonza Optimized Protocols or on results shared from customers who performed an optimization based on our guidelines. In case no data are shown for the selected Nucleofector™ Platform, please take a look at our optimization strategy to get further guidance on how to easily determine optimal Nucleofection conditions yourself.

Protocol	Kit	Program	Cells	Efficiency	Viable Cells	Substrate		Format	Platform
	R	U-009	2e5	62%	87%	Plasmid (general)	3 µg	100 µl	I/II/2b
	R	U-023	2e5	58%	87%	Plasmid (general)	3 µg	100 µl	I/II/2b

Citations

OSU-03012, a Novel Celecoxib Derivative, Is Cytotoxic to Myeloma Cells and Acts through Multiple Mechanisms

Categories:

Transfection

Authors:

Zhang S, Suvannasankha A, Crean CD, White VL, Johnson A, Chen CS, Farag SS

In:

Clin Cancer Res (2007) 13(16): 4750-4758

IM9

Transfection Information

Citations